Long-term treatment with Burosumab reduces disease burden in adults with X-linked hypophosphatemia
A rare metabolic bone disease of genetic origin: X-linked hypophosphatemia: Kyowa Kirin Co announced the publication of new data highlighting the sustained benefits of burosumab treatment in adults with X-linked hypophosphatemia (XLH), a…